ACXP Earnings

ACXP reported its FY2025Q3 earnings on 2025-11-12, showcasing a revenue of 0.00 against an estimate of 0.00, resulting in a 0% surprise. The EPS was -1.23, surpassing the expected -1.61 by 23.6% . The stock experienced a -10.75% price change on the earnings day and a -24.37% change over the next five days, reflecting market reactions to the results.

Following ACXP's FY2025Q3 earnings announcement on 2025-11-12, the stock price moved by -10.75% on the day of the release. Over the subsequent five days, it saw a -24.37% change. Historically, ACXP's stock price tends to shift by an average of +20.95% in the 10 days leading up to earnings and +0.22% in the 10 days following, providing insight into potential market.

For , analysts estimate ACXP’s annual revenue to reach undefined, while the EPS is projected at -1.00. These estimates reflect recent revisions, with revenue estimates revised Revenue Revise Upward by 3.17% and EPS estimates No Change by % over the past three months, indicating analyst expectation in the company’s performance.

The correlation between ACXP's stock price and earnings forecast revisions shows that positive revisions in revenue or EPS often strengthen the stock’s fundamentals. Over the past three months, revenue estimates for FY2025 were Revise Upward by 3.17%, while EPS estimates moved No Change by % . This trend suggests that price dips could present buying opportunities for investors.

Based on historical trends, ACXP's stock price typically moves by +20.95% in the 10 days before its earnings and +0.22% in the 10 days after. For the upcoming earnings, analysts expect an EPS of -1.00 and revenue of undefined.

The earnings call reveals both positive and negative aspects. On the positive side, there are significant cost reductions and potential regulatory advantages for ibezapolstat, supported by FDA designations. However, the company faces financial sustainability issues, with ongoing net losses and uncertainties in partnership timelines. The Q&A section showed management's cautious optimism but lacked concrete timelines or commitments, which could dampen investor confidence. Given these mixed signals, the stock is likely to remain stable in the short term, resulting in a neutral market reaction.